Routine therapeutic monitoring of the active metabolite of carbamazepine: Is it really necessary?

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F15%3A%230001044" target="_blank" >RIV/00064190:_____/15:#0001044 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11310/15:10318783
Result on the web
<a href="http://dx.doi.org/10.1016/j.clinbiochem.2015.05.014" target="_blank" >http://dx.doi.org/10.1016/j.clinbiochem.2015.05.014</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.clinbiochem.2015.05.014" target="_blank" >10.1016/j.clinbiochem.2015.05.014</a>

Result language
angličtina
Original language name
Routine therapeutic monitoring of the active metabolite of carbamazepine: Is it really necessary?
Original language description
Carbamazepine (CBZ) is primarily used in the treatment of epilepsy as well as trigeminal neuralgia. It is metabolised by the liver to its pharmacologically active metabolite carbamazepine-10,11-epoxide (CBZ-E), which is potentially toxic. The aim of our study was to measure CBZ and CBZ-E in our patient set and to consider the introduction of CBZ-E to routine therapeutic drug monitoring (TDM). High-performance liquid chromatography (HPLC) and Chemiluminescence Microparticle Immuno Assay (CMIA) methods for the measurement of CBZ were compared.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
CE - Biochemistry
OECD FORD branch
—

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)